$140,000 of NATERA INC lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Advocacy on importance of FDA's oversight of Laboratory Developed Tests and impact on industry and patients. Advocacy on CMS administrative procedures regarding Date of Service (DOS) for Laboratory testing for patients."
You can find more data on corporate lobbying on Quiver Quantitative.
NTRA Congressional Stock Trading
Members of Congress have traded $NTRA stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $NTRA stock by members of Congress over the last 6 months:
- REPRESENTATIVE JOSH GOTTHEIMER purchased up to $15,000 on 11/20.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
NTRA Insider Trading Activity
NTRA insiders have traded $NTRA stock on the open market 228 times in the past 6 months. Of those trades, 0 have been purchases and 228 have been sales.
Here’s a breakdown of recent trading of $NTRA stock by insiders over the last 6 months:
- MATTHEW RABINOWITZ (EXECUTIVE CHAIRMAN) has made 0 purchases and 20 sales selling 221,130 shares for an estimated $35,729,673.
- STEVEN LEONARD CHAPMAN (CEO AND PRESIDENT) has made 0 purchases and 28 sales selling 227,486 shares for an estimated $34,342,861.
- MICHAEL BURKES BROPHY (CHIEF FINANCIAL OFFICER) has made 0 purchases and 28 sales selling 89,312 shares for an estimated $14,895,534.
- ROELOF BOTHA has made 0 purchases and 5 sales selling 87,473 shares for an estimated $14,793,563.
- JONATHAN SHEENA has made 0 purchases and 76 sales selling 73,239 shares for an estimated $11,190,767.
- SOLOMON MOSHKEVICH (PRESIDENT, CLINICALDIAGNOSTICS) has made 0 purchases and 22 sales selling 50,752 shares for an estimated $8,089,477.
- DANIEL RABINOWITZ (SEC. AND CHIEF LEGAL OFFICER) has made 0 purchases and 13 sales selling 37,240 shares for an estimated $6,071,374.
- ROY D. BAYNES has made 0 purchases and 6 sales selling 37,230 shares for an estimated $5,439,564.
- JOHN FESKO (PRESIDENT, CHIEF BUS. OFFICER) has made 0 purchases and 13 sales selling 28,855 shares for an estimated $4,686,103.
- GAIL BOXER MARCUS has made 0 purchases and 16 sales selling 19,894 shares for an estimated $3,053,475.
- ROWAN E CHAPMAN sold 1,767 shares for an estimated $300,808
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
NTRA Hedge Fund Activity
We have seen 302 institutional investors add shares of NTRA stock to their portfolio, and 242 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ added 3,871,862 shares (+134.9%) to their portfolio in Q4 2024, for an estimated $612,915,754
- JPMORGAN CHASE & CO added 2,069,396 shares (+44.7%) to their portfolio in Q4 2024, for an estimated $327,585,386
- MILLENNIUM MANAGEMENT LLC removed 1,021,889 shares (-72.0%) from their portfolio in Q4 2024, for an estimated $161,765,028
- FRED ALGER MANAGEMENT, LLC removed 994,184 shares (-24.8%) from their portfolio in Q4 2024, for an estimated $157,379,327
- BLACKROCK, INC. added 947,457 shares (+11.5%) to their portfolio in Q4 2024, for an estimated $149,982,443
- ALLIANCEBERNSTEIN L.P. removed 893,203 shares (-53.8%) from their portfolio in Q4 2024, for an estimated $141,394,034
- GOLDMAN SACHS GROUP INC added 887,710 shares (+110.0%) to their portfolio in Q4 2024, for an estimated $140,524,493
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
NTRA Analyst Ratings
Wall Street analysts have issued reports on $NTRA in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 03/04/2025
- Bernstein issued a "Outperform" rating on 01/10/2025
- Cowen & Co. issued a "Buy" rating on 11/13/2024
- Jefferies issued a "Buy" rating on 11/13/2024
- Canaccord Genuity issued a "Buy" rating on 10/29/2024
To track analyst ratings and price targets for NTRA, check out Quiver Quantitative's $NTRA forecast page.
NTRA Price Targets
Multiple analysts have issued price targets for $NTRA recently. We have seen 3 analysts offer price targets for $NTRA in the last 6 months, with a median target of $160.0.
Here are some recent targets:
- Tycho Peterson from Jefferies set a target price of $182.0 on 11/13/2024
- Catherine Ramsey Schulte from Robert W. Baird set a target price of $160.0 on 11/13/2024
- Kyle Mikson from Canaccord Genuity set a target price of $150.0 on 10/29/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
